Equities
HKEX posts record profit on 19% revenue rise in first half of 2026
Hong Kong Exchanges and Clearing reported HK$16.7 billion in revenue and HK$10.6 billion in net profit for the first half of 2026, driven by strong trading volumes and derivatives activity. Interim dividend increased 24% to HK$7.43 per share.
Karnov shares surge 12.86% on Q2 2026 results, AI-driven margin gains
Karnov Group reported a 25% adjusted EBITA margin in Q2 2026, up from 23%, as its AI workflow launch boosted profitability. Shares jumped 12.86% in pre-market trading on the news.
Höegh Autoliners Q2 2026 profit falls 17% as fuel costs surge
Car carrier operator posts $86 million net profit despite 2.6% volume growth and $22 million fuel cost hit. Shares drop 12.6% after results.
Scatec Q2 2026 results: Obelisk project offsets revenue decline
Renewable energy developer reports 10% drop in EBITDA but cites Africa's largest hybrid project as key offset to flat revenues. Power production rises 21% year-over-year.
Nscale plans $3 bln US IPO as AI data center demand surges
London-based AI data center firm Nscale targets September listing to raise up to $3 billion, citing $51 bln in contracted revenue and 10 GW of planned power capacity.
HKEX posts record H1 2026 profit on trading surge, dividend hike
Hong Kong Exchanges and Clearing reported a 24% rise in H1 2026 profit as trading volumes hit records, with EPS beating estimates by 18%. First interim dividend raised to HKD 7.43 per share.
Karnov Group shares surge 12.9% on AI workflow rollout, Q2 profit beats
Swedish legal data provider Karnov Group posted a 2.4% organic sales increase in Q2 2026, with adjusted EBITA margin rising to 25% as its AI-driven workflow solution drove customer upgrades. Shares jumped 12.9% following the release.
U.S. stocks face midterm election jitters as 2018, 2022 patterns resurface
Historical midterm election years show S&P 500 volatility in late summer and fall, with sector rotations offering clues for 2026. RBC Capital Markets expects contained pullbacks unless recession or rate risks escalate.
Novonesis shares surge 9% after Q2 results, higher 2026 guidance and €1bn buyback
Danish biosolutions firm posts 9% organic sales growth in Q2, beats estimates, raises 2026 outlook and launches inaugural €1bn share repurchase program.
Panoro Energy shares drop 4% after H1 2026 update, CI-27 deal details emerge
Panoro Energy’s stock fell 4% in pre-market trading after releasing H1 2026 pro forma figures and confirming a $80 million acquisition in Ivory Coast. The CI-27 deal, funded via shares and debt, is expected to close by Q3.
Zelluna shares fall 3.6% after Q2 2026 clinical update
Norway-based biotech’s stock declines after first patient dosed in ZIMA-101 trial; cash runway extends into Q3 2027. CEO cites ‘defining’ quarter as trial advances.
Novonesis lifts 2026 outlook, shares surge 8.5% on earnings update
The Danish biosolutions firm raised its full-year organic growth target to 7%-8% and announced a €1 billion buyback program through 2029. Shares jumped 8.5% to $449.50 amid strong H1 sales and EBITDA growth.
EverBank explores sale process after 2023 private-equity buyout
Digital lender with $47 billion in assets weighs strategic options including sale or IPO. Private-equity owners acquired it from TIAA in 2023.
German DAX slips 0.34% in early trade as oil, yields weigh
European stocks opened lower Thursday as rising oil prices and bond yields pressured the DAX, while gains in Continental and Sartorius were offset by losses in Brenntag and Ströer.
European stocks hit August lows as bond yields surge, central banks stay hawkish
Stoxx Europe 600 extends losing streak to seven sessions amid rising long-term yields and hawkish central bank signals. Novonesis leads gains after strong earnings.
Kid ASA posts 6.8% Q2 2026 revenue rise, margin expansion
Norwegian home furnishings retailer Kid ASA reported second-quarter 2026 revenue of NOK 914.8 million, up 6.8% year-over-year, with gross margin expanding to 63.2% and EBITDA rising 15.2%.
Swiss SMI rebounds into positive territory after midday losses
The SMI turned positive by 0.15% after trading lower all day, with Roche and Novartis narrowing declines. Brent crude held above $93 a barrel amid Middle East tensions.
German DAX seen little changed as energy costs, yields weigh
Outlook for Frankfurt stocks points to muted trading as higher oil prices and rising bond yields offset regional tech rebounds. Sartorius gains on UBS upgrade.
BMO initiates coverage of semiconductor stocks with top picks
The bank has launched research coverage of chip sector equities, highlighting favored names for investors.
Moderna plunges 25% after cancer vaccine trial results fail to impress
Shares of Moderna fell sharply after a Phase 3 trial of its personalized mRNA cancer vaccine met endpoints but drew muted analyst reactions. Targets remain below prior close.
BCV posts 5% profit growth as new money inflows surge
Swiss cantonal bank's half-year profit rises despite flat net interest income, with CHF 2.4 bln in new client money driving asset growth to CHF 141.8 bln.
Norse Atlantic posts $132 mln Q2 loss as revenue falls short of forecast
Airline’s second-quarter revenue of $132 million missed a $1.65 billion target, while EBITDA widened to negative $8 million. Stock near 52-week low after bridge loan repayment.
Swedish cybersecurity firm Clavister posts 63% revenue surge in Q2
Clavister Holding AB reported a sharp increase in net sales to 89 million Swedish kronor, reversing a prior-year loss as operating profit reached 13 million kronor. The company cited strong order backlog and a growing sales pipeline.
Swiss stocks rise as 19 of 20 SMI components gain; Roche leads, Aryzta slumps
The SMI advanced 0.12-0.16% with Roche up 0.52% as 19 of 20 index members gained. Aryzta tumbled over 6% after UBS downgraded it to sell amid broader market strength.